Latest Payments News

Culpeo Minerals Limited reported a net cash outflow of $246,000 for the December 2024 quarter but retains robust liquidity with $3.7 million in available funding. The company’s cash position and financing facilities suggest it is well-positioned to continue its exploration activities.

Western Gold Resources Limited has secured expanded mining approvals, confirmed strong metallurgical recoveries, and updated its mineral resource estimate at the Gold Duke Project, positioning the company for a transition to production.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Peppermint Innovation Ltd has bolstered its financial position with a $3 million convertible note while navigating a challenging quarter marked by cybersecurity disruptions and strategic divestments. The company is poised for recovery with new advisory expertise and enhanced payment integrations in the Philippines.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Jindalee Lithium Limited reported a $935,000 net cash outflow for the December 2024 quarter, maintaining a cautious but confident stance on securing future funding to support ongoing exploration activities.

Oldfields Holdings Limited reports a robust second quarter for FY2025, highlighting successful strategic realignment and improved financial performance despite ongoing transition costs.

Great Northern Minerals Limited reports significant progress in the sale of its Golden Ant Mining project, with a $1.3 million Earn-In Stage payment expected soon, alongside notable board changes and strategic project reviews.

South Harz Potash Limited has made significant strides in acquiring the Sollstedt mine and secured approximately A$2.2 million in new equity, positioning itself to advance the Ohmgebirge project amid a strengthening potash market.

Rare Foods Australia reports an 18% biomass increase and $440k in cost savings, while launching its Subsea Estate brand and securing a $2.1M R&D refund to support growth.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Audalia Resources has completed a key drilling program at its Medcalf Project, delineating promising mineralisation zones while significantly boosting its cash reserves through a recent capital raise.